Condition: Pseudomonas Infections · Pseudomonas Aeruginosa · Prognosis · Sponsor: Centre Hospitalier Régional d'Orléans
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.
This description comes directly from the study's public registry record.
FRANCOIS BARBIER, Professor · +33238229939 · francois.barbier@chu-orleans.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens | Amiens, France | Not Yet Recruiting |
| CH Argenteuil | Argenteuil, France | Not Yet Recruiting |
| CH Bayonne | Bayonne, France | Not Yet Recruiting |
| CHU de BESANCON | Besançon, France | Not Yet Recruiting |
| CH Bethune | Béthune, France | Not Yet Recruiting |
| CHU Avicenne | Bobigny, France | Not Yet Recruiting |
| CH Bourgoin-Jallieu | Bourgoin, France | Not Yet Recruiting |
| CH Métropole Savoie | Chambéry, France | Not Yet Recruiting |
| Ch de Chartres | Chartres, France | Not Yet Recruiting |
| CHU Clermont Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| CHI Créteil | Créteil, France | Not Yet Recruiting |
| CHU Henri Mondor | Créteil, France | Not Yet Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06738771